Advanced

Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder

Eriksson, Pontus LU ; Sjödahl, Gottfrid LU and Liedberg, Fredrik LU (2017) In European Urology
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
European Urology
publisher
Elsevier
external identifiers
  • scopus:85019740982
ISSN
0302-2838
DOI
10.1016/j.eururo.2017.05.027
language
English
LU publication?
yes
id
757bcafc-c1c8-4ec6-85f1-10a6da05441c
date added to LUP
2017-06-16 12:41:11
date last changed
2017-06-18 03:00:04
@misc{757bcafc-c1c8-4ec6-85f1-10a6da05441c,
  author       = {Eriksson, Pontus and Sjödahl, Gottfrid and Liedberg, Fredrik},
  issn         = {0302-2838},
  language     = {eng},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder},
  url          = {http://dx.doi.org/10.1016/j.eururo.2017.05.027},
  year         = {2017},
}